IPSEN : RBC welcomes Cabometyx data
While full data are still required to assess its potential, RBC believes that 'strong data could support a significant boost to Cabometyx sales, currently driven by its use in the kidney cancer setting'.
In the meantime, Cabometyx will remain an important growth driver for Ipsen, particularly in first-line kidney cancer", says RBC, which anticipates sales of €546 million this year (+22%), and a peak of €786 million by 2028.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
Go to the original article.
Contact us to request a correction